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Introduction: Response-assessment metrics play an important role 
in clinical trials and routine patient management. For patients with 
malignant pleural mesothelioma (MPM), the standard for response 
assessment is image-based measurements of tumor thickness made 
according to the modified RECIST (Response Evaluation Criteria 
in Solid Tumors) protocol. To classify tumor response, changes in 
tumor thickness are compared with the standard RECIST −30% 
and +20% cutoffs for partial response (PR) and progressive disease 
(PD), respectively, which are not specific to MPM. The purpose of 
this work is to optimize the correlation between tumor response and 
patient survival by assessing the validity of existing response criteria 
in MPM and proposing alternative criteria.
Methods: Computed tomography measurements of tumor thickness 
were acquired at baseline and throughout treatment for 78 patients 
undergoing standard-of-care chemotherapy. Overall survival was cor-
related with best response and first follow-up response using Harrell’s 
C statistic. The response criteria for PD and PR were each varied in 
1% increments to obtain optimized classification criteria. The perfor-
mance was cross-validated using a leave-one-out approach.
Results: Median survival was 14.9 months. The performance of 
the standard RECIST criteria in correlating response with survival 
was C=0.778, whereas the optimized performance of C=0.855 was 
obtained with criteria of −64% for PR and +50% for PD. After cross-
validation, this performance was slightly reduced to C=0.829.
Conclusions: Optimized tumor-response classification criteria were 
obtained for patients with MPM. These criteria improve the correla-
tion between image-based response and patient survival.
Key Words: Malignant pleural mesothelioma, Therapy response 
assessment, Chest computed tomography.
(J Thorac Oncol. 2012;7: 1728–1734)
Malignant pleural mesothelioma (MPM) is a malignancy of the pleural lining separating the lungs and the tho-
racic wall and is primarily caused by exposure to asbestos.1 
Although evidence suggests that the disease may have peaked 
in the United States in the past decade, European incidence 
is not forecast to peak until the next decade, and incidence in 
countries that continue to use asbestos in new buildings will 
continue to increase.2,3 These facts, along with poor prognosis 
for the disease, highlight the necessity for effective treatments 
for mesothelioma.4
Before effective treatments may be discovered, a surro-
gate of efficacy for early clinical drug development is required, 
which is the purview of current response-assessment metrics. 
The assessment of disease response to therapy is a vital com-
ponent of oncologic patient care and clinical trials. As Nowak5 
states in a 2005 article, 
A decrease in tumor size may or may not achieve palliation in indi-
vidual patients. However, tumor response is an important surrogate 
for patient benefit in non-randomized clinical trials where symptom 
improvement and increased survival are difficult to assess.
The current clinical method for tumor response assessment 
in mesothelioma is the modified Response Evaluation Criteria 
in Solid Tumors (RECIST) guidelines, which calls for two lin-
ear measurements of tumor thickness to be summed from each 
of three axial sections, primarily in computed tomography (CT) 
scans.6,7 To classify patients into response categories, progres-
sive disease (PD) is a summed measurement increase between 
scans larger than 20%, partial response (PR) is a summed mea-
surement decrease of 30% or more, and stable disease (SD) 
is any measurement change between −30% and +20%. These 
classification criteria are the same as the original RECIST crite-
ria for solid tumors.8 However, the original RECIST classifica-
tion criteria are based on an extrapolation of the 1981 World 
Health Organization bidimensional criteria, which categorize 
PD as an increase in the bidimensional measurement of 25% 
or more and PR as a bidimensional measurement decrease of 
50% or more.9 These classification criteria for two-dimensional 
measurements were converted to classification criteria for one-
dimensional measurements, using an assumption of spherical 
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volume geometry and subsequently rounded, leading to the cur-
rent RECIST classification criteria.10,11 Incidentally, the World 
Health Organization −50% and +25% criteria were based, in 
part, on previous breast cancer cohort studies that investigated 
the minimum change in tumor burden that could be identified 
reliably by physicians through palpation.
The history of the RECIST classification criteria casts 
some doubt on the applicability of such criteria for classification 
of response in a disease so typically aspherical as mesothelioma 
(Fig. 1). Indeed, others have investigated alternate volume-
equivalent response-classification criteria for mesothelioma 
based on theoretical geometric models other than spheres, such 
as the lens, crescent, or annulus.12 On the whole, these geomet-
ric models indicate that linear measurements acquired accord-
ing to the modified RECIST guidelines would more closely 
approximate the corresponding volume changes seen in tumors 
of spherical morphology if the definition of stable disease were 
broader. Although these models raise important issues, they 
are still theoretical derivations. Image-based response assess-
ment is often used as a surrogate for patient benefit in clinical 
trials, and therefore, the most useful (and relevant) response-
classification criteria would be those developed to maximize the 
surrogacy of the assessment metric for meaningful outcomes 
such as survival. The purpose of this work is to optimize the 
disease-specific response-classification criteria by maximizing 
the association between response assessment and overall sur-
vival in patients with MPM treated with chemotherapy.
PATIENTS AND METHODS
Patients
Imaging and clinical data from 78 patients were 
obtained retrospectively from a prospective study involving 
fluorodeoxyglucose positron emission tomography (FDG-
PET) and CT imaging of MPM.13 All patients were more than 
18 years of age with histologically or cytologically confirmed 
MPM and had not received prior chemotherapy or radiother-
apy. Original patient accrual occurred from late 2003 to 2010, 
and the original study was approved by the local institutional 
Human Research Ethics Committee at Sir Charles Gairdner 
Hospital (Nedlands, Western Australia, Australia), with 
patients providing written consent. The retrospective analysis 
of the Health Insurance Portability and Accountability Act 
(HIPAA)-compliant data was approved by both the originat-
ing institution’s Human Research Ethics Committee and the 
Institutional Review Board at The University of Chicago, 
where the analysis was performed. Because the original study 
was not a treatment study, patients were treated as clinically 
indicated. Initially, the combination chemotherapy consisted 
of cisplatin and gemcitabine and later, when it became avail-
able at the original study institution, cisplatin and pemetrexed. 
Palliative radiotherapy was used when indicated, and a single 
patient had undergone previous pleurectomy/decortication.
Imaging
Patients were imaged using helical CT up to 1 month 
before the first cycle of chemotherapy and throughout their 
treatment regimen (typically after the first cycle, and then 
every 2 cycles). Images were reconstructed axially with 5-mm 
slices. CT staging was performed according to the Union for 
International Cancer Control tumor, node, metastasis staging 
system (2002). CT scans were staged by a thoracic radiologist 
or medical oncologist experienced in mesothelioma imaging, 
and tumor measurements were acquired clinically according 
to the modified RECIST protocol on baseline and all follow-
up scans.6 Pathologic staging was not performed. The clinical 
measurement protocol dictated that all imaging examinations 
from an individual patient be measured by the same clini-
cian in an attempt to minimize variability. Initially, radiologic 
response was classified according to the standard RECIST 
criteria, where PR is a 30% reduction in tumor thickness over 
baseline, PD is a tumor thickness increase of 20% more than 
the nadir measurement, and SD is attributed to patients who 
failed to meet the criteria for either of the other categories.
Correlating Response with Survival
To measure the association between patient response 
classification and survival, a single response category must 
be assigned to each patient. This single response category can 
be assigned in multiple ways, for instance, the best response 
for the patient achieved during a time interval (usually over 
the active treatment period) can be used, where PR is better 
than SD, and SD is better than PD. Alternatively, response at 
a predetermined follow-up time could be equally important. 
In this study, both the best response and response at the first 
follow-up scan were investigated.
If the response-assessment system is to provide an accu-
rate correlate of survival (measured from diagnosis), patients 
FIGURE 1. The aspherical shape of malignant pleural meso-
thelioma (solid white arrows) differs fundamentally from the 
assumptions inherent in the standard RECIST classification 
criteria. RECIST, Response Evaluation Criteria In Solid Tumors.
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labeled as PR should survive longer than those patients labeled 
as SD, and both groups should survive longer than patients 
labeled as PD. The extent to which the desired trend holds true 
can be measured quantitatively using Harrell’s C statistic.14 A 
value of C=0.5 is equivalent to classification by chance alone, 
whereas C=1.0 would indicate perfect separation of response 
groups with respect to subsequent survival times. According 
to Harrell, C>0.65 indicates clinical utility, whereas C>0.80 
indicates high predictive accuracy.14 The numerical value of 
C can be interpreted as the fraction of patient comparisons 
that would be concordant. All analyses were performed using 
the academic edition of Revolution R Enterprise (version 4.3, 
based on R version 2.12), and C was implemented in the R 
package “Hmisc.”15,16
Optimization and Cross-Validation
To determine the optimal set of response-classification 
criteria, the PR and PD cutoffs were varied in 1% increments 
(i.e., the PR cutoff was swept from −100% to 0% in 1% incre-
ments, and the PD cutoff was swept from 0% to 100% in 1% 
increments). For each possible pair of cutoff criteria, the cor-
relation between response and survival was assessed to yield 
one value of C. By tabulating the values of C across all possi-
ble response criteria, the optimal pair of classification criteria 
was determined. These optimal cutoffs represent the classifi-
cation criteria for which the correlation between response and 
patient survival is greatest. The criteria derived in this way, 
using all 78 patients, will be called the full cohort criteria.
The optimization process requires validation because 
the most optimal model from the full patient cohort has a 
strong tendency to yield an overly optimistic prediction 
rule with respect to predictions on de novo observations not 
involved in model building. A leave-one-out cross-validation 
(LOOCV) process may thus generate a more realistic value 
of C.14,17 Using LOOCV, each patient was excluded, one at 
a time, and the classification criteria were optimized using 
the other 77 patients. The optimized criteria from these 77 
training patients were used to test the model on the seventy-
eighth patient, who had been excluded from model optimiza-
tion. LOOCV allows each patient to be assigned to a response 
category using criteria that were derived without knowledge 
of that particular patient’s tumor measurements, and the 
LOOCV-based value of C is a better indicator of how well 
the reported classification criteria will perform for a new and 
previously unknown patient.
Two additional internal validation checks were also 
performed. First, to evaluate possible dependence of the clas-
sification rule and C derived to specific cases or subsets of 
cases, bootstrap samples from the entire cohort were gener-
ated and the optimization procedure repeated, followed by 
a descriptive summary of the cutoffs and C values. Second, 
to evaluate the performance of the derived rule from the full 
cohort in hypothetical independent patient cohorts, the rule 
was applied to random bootstrap subcohorts and the perfor-
mance summarized.
Finally, some inferential procedures were carried out 
comparing the C statistics for the standard RECIST approach 
versus the optimized classification criteria. When estimates 
of C are calculated, standard errors (SE) are also calculated 
for the metric. However, the estimates of the performance 
of the standard RECIST classification criteria, C
std
, and the 
optimized classification criteria performance, C
opt
, will neces-
sarily be correlated for a given patient sample. Therefore, to 
compare differences in point estimates of C, one must account 
for this correlation because an assumption of independence 
would result in an overly conservative p value. Correlation 
was calculated using a jackknife approach on the LOOCV 
patient subsets with analysis of variance modeling, similar to a 
method previously described for receiver operating character-
stic curves.18,19 Finally, to account for the correlation between 
point estimates of C, C
opt
 was compared with C
std
 using a one-
sided Z-test with p value greater than 0.05 as the standard for 
statistical significance.
RESULTS
Patients and Overall Survival
Of the 78 MPM patients included in this study, 66 were 
men and 12 were women. The median patient age at study entry 
was 66 years (range, 41–80 years). Most patients (n = 56) had 
epithelioid histology, with a smaller number of patients hav-
ing biphasic (n = 15), or sarcomatoid (n = 7) histology. A total 
of 275 CT scans were included in this study, with a median 
of four scans per patient (including baseline scans). Eleven 
patients had only a baseline scan with one follow-up scan, 
whereas 25 patients had three scans total, 32 patients had four 
scans total, and 10 patients had five scans total. The median 
duration between scans was 45 days. CT staging identified 11 
patients as stage I, three patients as stage II, 34 patients as 
stage III, and 30 patients as stage IV. Median survival was 21.8 
months for stage I patients, not available for stage II patients 
(only 1 death and 2 censoring events occurred), 14.8 months 
for stage III patients, and 13.6 months for stage IV patients. 
The difference in survival between stages was not significant 
by a log-rank test (p > 0.05).
Median overall survival from diagnosis was 14.9 
months (range, 2.5–60 months). Of the 78 patients, there were 
75 observed deaths, and three patients were lost to follow-up 
after a median follow-up of 35 months. The overall survival 
curve is shown in Figure 2.
Optimization of Classification Criteria
Using the standard RECIST classification criteria of 
−30% for PR and +20% for PD, the correlation between best 
response and overall survival was Cstd
best
 = 0.778 with an SE 
of 0.048. The correlation between first follow-up response 
for each patient and overall survival was Cstd
first = 0.655 with 
an SE of 0.054. After optimization, the new classification 
criteria derived from the full cohort was −64% for PR and 
+50% for PD. Optimizing the correlation between response 
classification and survival resulted in identical criteria when 
using both the best response and first follow-up response per 
patient. The performance of these full cohort criteria using 
the best response per patient was Copt
best = 0.855 with an SE of 
0.045, and using the first follow-up response per patient, the 
performance was Copt
first
 = 0.932 with an SE of 0.029. These 
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values are summarized along with their p values comparing 
optimized performance with the standard RECIST classifica-
tion criteria performance in Table 1.
Figure 3 plots overall survival from diagnosis against 
best response for each patient using both the standard 
RECIST classification criteria and the optimized criteria. 
It can be seen that after optimization, the classification cri-
teria groups patients into only two response categories; the 
two patients originally classified as PD are now included in 
the SD category. Furthermore, many of the patients origi-
nally classified as PR but having short survival durations 
are now included in the SD category. Figure 4 plots survival 
curves for the best response categories using both the stan-
dard RECIST classification criteria and the optimized cri-
teria. Using the standard RECIST classification criteria, 
the median survival for best response PD, SD, and PR was 
11.5 months, 11.6 months, and 23.0 months, respectively. 
Using the optimized classification criteria, the median sur-
vival for best response SD and PR was 12.9 months and 
24.8 months, respectively.
Table 2 shows a cross-tabulation of how patients are 
categorized using the standard RECIST and optimized clas-
sification criteria for both the best response and first follow-up 
response. For best response, 17 patients (22%) changed clas-
sification categories between the standard RECIST criteria 
and optimized criteria, and for first follow-up response, 10 
patients (13%) changed classification categories.
Cross-Validation of Classification Criteria
As indicated above, cross-validation of the optimized 
classification criteria leads to a more realistic value of 
model performance, C
cv
. Correlating each patient’s cross- 
validated best response with overall survival, a performance of 
Ccv
best = 0.829 with an SE of 0.043 was achieved. When the 
cross-validated first follow-up response was correlated with 
overall survival, the model performance was Ccv
first = 0.872 
with an SE of 0.049. The LOOCV scheme is more a valida-
tion of the optimization process than any one set of optimized 
criteria, and therefore, these C metrics are more realistic esti-
mates of performance without the bias of training and testing 
a model on the same patient cohort. These C values, along 
with p values comparing cross-validated performance with the 
standard RECIST performance, are summarized in Table 1.
From the first bootstrap internal validation, where the 
classification criteria for best response were allowed to vary with 
each indepen dent bootstrap patient sample, the criteria selected 
for each independent bootstrap sample are summarized as fol-
lows. The PR cutoff had a median value of −64%, with a mode 
of −64% and a mean of −67%, and the PD cutoff had a median 
value of +50%, with a mode of +50% and a mean of +36%. 
In the second bootstrap internal validation, where the classifi-
cation criteria were fixed at −64% and +50%, the mean per-
formance across independent bootstrap samples was Cboot opt
best
,  = 
0.852 with an SE of 0.047. For the same independent bootstrap 
samples, the mean performance of the standard RECIST cri-
teria was Cboot std
best
,  = 0.778 with an SE of 0.050. A comparison 
of these bootstrap performance values and their respective SEs 
with the values in Table 1 reveals them to be quite similar.
DISCUSSION
To assess patient response to therapy, clinicians have 
come to rely on image-based measures of tumor burden as a 
surrogate for true patient benefit (i.e., reduced symptom bur-
den or time until a defined event such as death). One common 
method for image-based assessment is the RECIST paradigm 
of linear measurements and response-classification criteria. 
Although the specific technique used to acquire tumor mea-
surements has been defined in a specific sense for patients with 
MPM (modified RECIST), the response-classification criteria 
for MPM patients are the same as those used for all tumors 
based on standard RECIST, which defines PD as a 20% or 
more increase from measurement nadir, PR as a decrease of 
30% or more from baseline, and stable disease (SD) as any-
thing between these cutoffs. However, these classification cri-
teria may not be optimal for any specific disease.20 Our aim in 
this study was to optimize the correlation between response 
classification and overall survival for MPM patients by vary-
ing the classification criteria.
The first step in this work was to quantify the relationship 
between response classification and survival for the standard 
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TABLE 1.  Correlation Scores Between Patient Response and 
Overall Survival From Diagnosis
Classification Criteria C
Standard 
Error
p 
value 
Best response
Standard RECIST (−30%/+20%) 0.778 0.048 —
Optimized (−64%/+50%) 0.855 0.045 0.039
Cross-validation 0.829 0.043 0.121
First follow-up response
Standard RECIST (−30%/+20%) 0.655 0.054 —
Optimized (−64%/+50%) 0.932 0.029 <0.001
Cross-validation 0.872 0.049 <0.001
All p values are calculated with reference to the appropriate standard RECIST 
classification criteria performance (either best response or first follow-up response per 
patient) and properly account for correlation between values of C.
RECIST, Response Evaluation Criteria In Solid Tumors.
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RECIST classification criteria. If response classification 
based on linear measurements were perfectly associated with 
survival, every patient classified as PR would live longer 
than every patient classified as SD, and both classes would 
live longer than every patient classified as PD. When this 
relationship holds true, C = 1.0. Using the modified RECIST 
measurement technique and the standard RECIST −30% and 
+20% criteria, we found a correlation of C
std
 = 0.778 between 
best patient response and survival.
Although the performance of the standard RECIST cri-
teria is within the range of clinical utility according to Harrell, 
performance could be improved by changing the response 
classification criteria to −64% and +50%. The performance 
of these criteria was measured as C
opt
 = 0.855. To avoid bias 
that may result from training and testing on the same group of 
patients, a cross-validation approach was used to estimate an 
unbiased performance of C
cv
 = 0.829, which is in the range of 
high predictive accuracy. Although comparing the full cohort 
performance (0.855) with the standard RECIST performance 
(0.778) yields a p value of 0.039, the cross-validated p value 
was 0.121. These p values are calculated by considering the 
point estimates of C and their respective SEs and the correla-
tion between the two metrics. For a given group of patients, 
values of C from different classification criteria will be cor-
related because of the overlap between the discrete response 
categories. Although C
opt
 is significantly larger than C
std
, C
cv
 is 
still larger than C
std
, though not significantly so.
Using the optimized response-classification criteria, 
no patients are classified as having PD as their best response. 
Although this is a byproduct of our particular patient sample, 
the effective reduction in response categories from three to 
two is actually in line with phase II trials, where classification 
into only two categories is common (responders and nonre-
sponders). In fact, if the abovementioned optimization process 
is conducted with only one cutoff to start with instead of two, 
the same −64% criterion is obtained to separate a responder’s 
category from that of a nonresponder. Some care also needs 
to be taken when interpreting the optimized criteria in terms 
of first follow-up response. With wider criteria, nearly all 
patients were classified as SD (77 of 78) because there has 
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cation criteria and each patient’s best response. B, using the 
optimized −64%/+50% response criteria. No patients were 
classified as having progressive disease with the optimized 
criteria. RECIST, Response Evaluation Criteria In Solid Tumors.
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usually not been enough time for tumor burden to change dra-
matically in either direction. The patient imaging series used 
in this study are from routine clinical practice; patients who 
had PD, unacceptable toxicity, or wished to stop treatment for 
other reasons did not continue with CT imaging if care was 
subsequently palliative only. In this context, baseline imaging 
with two additional scans equates to four cycles of chemother-
apy, and it is not uncommon to cease treatment at this point in 
the context of substantial toxicity, even with SD. Patient best 
response is usually achieved only after a number of treatment 
cycles, so despite the improved performance of the optimized 
criteria on the first follow-up response compared with stan-
dard RECIST, this study does not go so far as to advocate that 
all patient response should be assessed after only one follow-
up scan. In standard clinical treatment, patients are treated as 
long as is practical and advisable to achieve the best response 
possible, and therefore, we believe that the improved perfor-
mance of the optimized classification criteria for best response 
is more clinically relevant than the improved performance for 
first follow-up response.
The issue of disease progression is also important in the 
context of initiating or withdrawing patient treatment. Many 
clinical trials incorporate PD as an eligibility criterion, use 
PD as a trigger to cease study treatment, and establish pro-
gression-free survival as an important endpoint. All these set-
tings would be impacted by the classification criteria proposed 
in this study. As this study was not originally an intervention 
study, we are unable to determine the impact of the proposed 
criteria on initiation of patient treatment. Of the 78 patients, 
19 experienced disease progression according to the standard 
RECIST classification criteria at some point during their treat-
ment, with a median time-to-progression of 5.0 months and a 
median overall survival of 14.9 months. Using the proposed 
classification criteria, however, only seven patients experi-
enced disease progression at some point during their treat-
ment, with a median time-to-progression of 5.9 months and 
a median overall survival of 14.9 months. Using these revised 
criteria, patients may be eligible for clinical trials later and 
stay on treatment longer. To validate appropriate criteria for 
progression, it may be more appropriate to identify tumor 
thickness changes that correspond to meaningful deteriora-
tion in other patient-rated outcomes such as dyspnea, pain, 
and quality of life.
Previously, theoretical studies explored the possibility 
of alternate response criteria for MPM by investigating linear 
measurement cutoffs in aspherical geometries. Oxnard et al12  
obtained classification criteria of −67.9% and +100.1% for 
an annulus, −51.5% and +45.4% for a lens, and −65.8% and 
+73.6% for a crescent geometry with linear measurements 
made according to the modified RECIST protocol. These 
alternate criteria are all substantially wider than the standard 
RECIST criteria, as are the optimized criteria we derived in 
this study; however, the theoretical criteria of Oxnard et al12 
were all based on volumetric equivalence to −30% and +20% 
changes in the diameter of a sphere, and the somewhat arbi-
trary provenance of those original criteria have been outlined 
earlier.
This study sought to identify classification criteria that 
optimized correlation with overall survival. To fully validate 
these new response criteria derived from this moderately sized 
database, they must be tested on larger independent patient 
cohorts. Although the LOOCV used in this study attempts to 
simulate this process, it is not a substitute for a full independent 
validation, and future work will seek to validate these proposed 
response criteria. We also caution that although these criteria 
predict survival in patients on cytotoxic chemotherapy, it is 
unclear whether they would be a valid candidate surrogate 
for survival benefit in patients receiving a targeted therapy. 
Because the variability in manual measurements has been 
well documented,21 it is possible that measurements from 
different observers would have resulted in different optimized 
classification criteria, and future studies will incorporate 
measurements from multiple observers to assess interobserver 
variability. Finally, because the patient cohort was acquired 
from a previous study involving FDG-PET imaging for 
patients with MPM,13 we look forward to investigating joint 
correlations between response as assessed using FDG-PET 
imaging parameters (e.g., standardized uptake value or total 
glycolytic volume) and response as assessed using modified 
RECIST measurements in a future study.
To summarize, the current standard for response assess-
ment in patients with MPM is a set of linear tumor thickness 
measurements acquired according to the modified RECIST 
protocol. Changes in these tumor measurements are compared 
with classification criteria, currently defined as −30% for PR 
and +20% for PD. Despite the original arbitrary provenance 
of these cutoffs, they perform adequately when correlated 
with patient survival and are within the range of clinical util-
ity. However, by changing these criteria to −64% and +50%, 
respectively, the correlation between tumor response and over-
all survival is improved. These optimized classification criteria 
seem better suited to the specific morphology and growth pat-
tern of mesothelioma and may prove useful in the assessment of 
clinical trials and routine patient care.
TABLE 2. Number of Patients in the Different Response 
Categories Using the Standard RECIST Classification Criteria 
and the Optimized −64%/+50% Classification Criteria
Optimized Classification 
Criteria
PR SD PD
(a) Best Response
PR 11 15 0
Standard classification criteria SD 0 50 0
PD 0 2 0
(b) First follow-up response
PR 1 8 0
Standard classification criteria SD 0 67 0
PD 0 2 0
Response classified according to best response is shown in (a), whereas response 
classified according to first follow-up response is shown in (b).
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